Association of hypoglycemic agents with the risk of platinum-based chemotherapy-induced peripheral neuropathy in patients with type 2 diabetes mellitus - PubMed
3 hours ago
- #Chemotherapy-induced peripheral neuropathy
- #SGLT2 inhibitors
- #Type 2 diabetes
- Study investigates the association between hypoglycemic agents and the risk of platinum-based chemotherapy-induced peripheral neuropathy (CIPN-P) in type 2 diabetes patients.
- A retrospective cohort study using Japanese claims data from 119,061 patients with type 2 diabetes on hypoglycemic agents and platinum-based chemotherapy.
- CIPN-P was defined as a new prescription of specific neuropathy drugs following a peripheral neuropathy diagnosis, with patients followed for three years.
- Incidence of CIPN-P was 18.9%, and sodium-glucose cotransporter 2 inhibitors (SGLT2i) were associated with a lower risk (HR 0.89, 95% CI 0.82-0.96).
- Specifically, empagliflozin and dapagliflozin each had a hazard ratio of 0.85, indicating a significant reduction in CIPN-P risk.
- Findings suggest SGLT2 inhibitors may mitigate CIPN-P risk, supporting individualized antidiabetic treatment strategies during platinum-based chemotherapy.